NASH WEBINAR:
Nonalcoholic Steatohepatitis: Update and Future Perspectives
In collaboration with Echosens™, we presented the webinar ”Nonalcoholic Steatohepatitis: Update and Future Perspectives”.
Topics addressed during this webinar:
˃ NASH early identification, patients at risk, diagnostic algorithm and FibroScan
˃ Implementation of a patient care path and guidelines
˃ Ongoing trials, drug development and expectations for introduction in clinical practice
This webinar was presented by:
˃ Dr. Onno Holleboom – Internist and endocrinologist(speaker)
˃ Dr. Manuel Castro Cabezas – Internist (speaker)
˃ Prof. Rick Grobbee – Professor of Clinical Epidemiology (host)
Curious about the latest insights about NASH? Watch the webinar ”Nonalcoholic Steatohepatitis: Update and Future Perspectives”.
Topics addressed during this webinar:
˃ NASH early identification, patients at risk, diagnostic algorithm and FibroScan
˃ Implementation of a patient care path and guidelines
˃ Ongoing trials, drug development and expectations for introduction in clinical practice
This webinar was presented by:
˃ Dr. Onno Holleboom – Internist and endocrinologist(speaker)
˃ Dr. Manuel Castro Cabezas – Internist (speaker)
˃ Prof. Rick Grobbee – Professor of Clinical Epidemiology (host)
Curious about the latest insights about NASH? Watch the webinar ”Nonalcoholic Steatohepatitis: Update and Future Perspectives”.
NASH CLinical video
Every now and then an article on NASH is published which is relevant for both clinicians and scientists. "Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum", by Cheung et al* is such an article. When can we speak of a real improvement due to treatment in NASH patients? If you happen to have 5 minutes left, have a look at this NASH Clinical video! We think it is worthwhile.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
| defining_improvement_in_nonalcoholic_steatohepatitis |
GLOBAL NETWORk
Key research questions can only be answered through multidisciplinary and networking approaches.
NASH Clinical was founded in Zeist, the Netherlands in December 2018 by Julius Clinical, an Academic Research Organization. NASH Clinical is a fully independent research network with the mission to decrease the global NASH problems. The founding members, who share many values professionally, had already been connected through research, education or other network activities.
NASH Clinical is a global network of clinicians / investigators. Participating clinicians are: endocrinologists, gastro-enterologists, diabetologists and general internists. There are connections with a dozen of hospitals in the Netherlands and many hospitals worldwide.
NASH Clinical was founded in Zeist, the Netherlands in December 2018 by Julius Clinical, an Academic Research Organization. NASH Clinical is a fully independent research network with the mission to decrease the global NASH problems. The founding members, who share many values professionally, had already been connected through research, education or other network activities.
NASH Clinical is a global network of clinicians / investigators. Participating clinicians are: endocrinologists, gastro-enterologists, diabetologists and general internists. There are connections with a dozen of hospitals in the Netherlands and many hospitals worldwide.
NASH Clinical is a Julius Clinical Network.
Julius Clinical has a strong track record of expertise and performance in the field of cardiovascular diseases and the related field of metabolic diseases.
Read more about Julius Clinical here.
Julius Clinical has a strong track record of expertise and performance in the field of cardiovascular diseases and the related field of metabolic diseases.
Read more about Julius Clinical here.
WHAT IS NASH?
|
NASH is an acronym that stands for Non-Alcoholic SteatoHepatitis. It is the most severe form of non-alcoholic fatty liver disease (NAFLD), and is characterized by the presence of an abnormal accumulation of fat in the liver which in some individuals can progress to liver cell injury (hepatocellular ballooning) and inflammation. As NASH evolves, over time it can result in excessive scarring in the liver (fibrosis), a natural response to injury which can lead to liver cirrhosis or liver cancer.
NAFLD is often associated with insulin resistance and is strongly associated with type 2 diabetes mellitus and obesity. In addition to being at risk for NASH, cirrhosis and its complications, NAFLD patients are also at higher risk of cardiovascular diseases (CVD), including coronary heart disease and stroke. NAFLD confers increased cardiovascular disease risk independent of traditional cardiovascular risk factors and metabolic syndrome. Individuals with NASH, have a high frequency of metabolic co-morbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. |
Bron: The NASH education program
|
lifestyle disease
NASH is closely related to the epidemic of obesity, pre-diabetes, and diabetes, and can be defined as the liver manifestation of the metabolic syndrome. It is heavily influenced by lifestyle (e.g. chronic excessive calorie intake, sedentary activity) and is distinct from other fatty liver diseases caused by alcohol abuse or medication side effects
Nowadays NASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes NASH a serious burden of disease. So, there is an urgent need for effective drugs.
Nowadays NASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes NASH a serious burden of disease. So, there is an urgent need for effective drugs.
WHY NASH CLINICAL?
Interdisciplinary collaboration is needed to combat NASH and consequently we have created NASH clinical network. The aim of this network is to share insights about this endemic disease, to collaboratively create easy-and-accurate diagnostic tools to identify these patients, and to conduct clinical trials to mitigate the potentially deleterious outcome of this disease.
THE TEAM
Manuel Castro Cabezas, PhD. Senior Consultant Internal Medicine, Endocrinology, Diabetes and Vascular Medicine at the Franciscus Gasthuis & Vlietland hospital in Rotterdam, the Netherlands Scientific Officer, Julius Clinical Academic Research Organization 
Leyla Kragten-Tabatabaie, PhD. Associated Director Scientific networks, Julius Clinical Academic Research Organization Board of Directors, ReSViNET foundation |
Christophe Moreno Professor in Gastroenterology and Hepatology Clinical Director of the Liver Unit at CUB Hôpital Erasme, Brussels, Belgium Consultant to the NASH Clinical team 
Prof. dr. Joost Hoekstra Professor of Medicine, University of Amsterdam’s Faculty of Medicine (AMC-UvA) Scientific Officer, Julius Clinical Academic Research Organization |
Prof. dr. Diederick E. Grobbee Professor of Clinical Epidemiology, UMC Utrecht Past president European Association for Preventive Cardiology, ESC. Chief Scientific Officer, Julius Clinical Academic Research Organization 
Lotte van Barneveld Marketing Manager, Julius Clinical Academic Research Organization |
| privacy_statement_website_-_english_-_nash_clinical_-_06sep2019.pdf |
